Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
Citação
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, v.30, n.17, Special Issue, p.1895-1905, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Obesity is a prevalent chronic disorder and a well-known risk factor for cardiovascular disease. However, the evidence of treating obesity for primary prevention of major cardiovascular events is still scarce and controversial. In this review, we provided a comprehensive description of the current evidence in treating obesity regarding cardiovascular protection. Bariatric surgery appears to be the most robust method to reduce events in people without established cardiovascular disease. High compliance to lifestyle interventions can further reduce cardiovascular risk. Concerning pharmacological therapies, a post hoc analysis from SUSTAIN-6 and a meta-analysis from STEP trials suggest that semaglutide, a GLP-1 receptor agonist, could reduce cardiovascular events in people without established cardiovascular disease. The first study addressed specifically a high-risk population with diabetes and, the second, low- or intermediary-risk individuals without diabetes. Tirzepatide, a novel dual GIP/GLP-1 agonist, although not yet tested in specific cardiovascular outcomes trials, could be an alternative since it induces loss in weight similar to the achieved by bariatric surgery. Therefore, extrapolated data in distinct baseline cardiovascular risk populations suggest that these two drugs could be used in primary prevention with the aim of preventing cardiovascular events, but the grade of this evidence is still low. Specifically designed studies are needed to address this specific topic.
Palavras-chave
Obesity, Cardiovascular disease, GLP-1 receptor agonist, Tirzepatide, Bariatric surgery
URI
https://observatorio.fm.usp.br/handle/OPI/57906
Referências
  1. Allison DB, 2012, OBESITY, V20, P330, DOI 10.1038/oby.2011.330
  2. Aminian A, 2020, ANN SURG, V272, P639, DOI 10.1097/SLA.0000000000004369
  3. Aminian A, 2019, JAMA-J AM MED ASSOC, V322, P1271, DOI 10.1001/jama.2019.14231
  4. [Anonymous], 2022, WORLD OB ATL 2022
  5. [Anonymous], NEWS DET
  6. [Anonymous], 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]
  7. Apovian CM, 2013, OBESITY, V21, P935, DOI 10.1002/oby.20309
  8. Ardissino M, 2021, J DIABETES, V13, P640, DOI 10.1111/1753-0407.13151
  9. Aroda VR, 2023, LANCET, V402, P693, DOI 10.1016/S0140-6736(23)01127-3
  10. Aronne LJ, 2013, OBESITY, V21, P2163, DOI 10.1002/oby.20584
  11. Astrup A, 2012, INT J OBESITY, V36, P843, DOI 10.1038/ijo.2011.158
  12. Bavishi C, 2022, AM J CARDIOL, V175, P182, DOI 10.1016/j.amjcard.2022.04.030
  13. Bertoluci MC, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098-017-0225-1
  14. Bezin J, 2023, DIABETES CARE, V46, P384, DOI 10.2337/dc22-1148
  15. Blackman A, 2016, INT J OBESITY, V40, P1310, DOI 10.1038/ijo.2016.52
  16. Blonde L, 2022, ENDOCR PRACT, V28, P923, DOI 10.1016/j.eprac.2022.08.002
  17. Blundell J, 2017, DIABETES OBES METAB, V19, P1242, DOI 10.1111/dom.12932
  18. Bohula EA, 2018, NEW ENGL J MED, V379, P1107, DOI 10.1056/NEJMoa1808721
  19. Bray GA, 1999, DIABETES CARE, V22, P623
  20. Caleyachetty R, 2017, J AM COLL CARDIOL, V70, P1429, DOI 10.1016/j.jacc.2017.07.763
  21. Carlsson LMS, 2020, NEW ENGL J MED, V383, P1535, DOI 10.1056/NEJMoa2002449
  22. Caterson ID, 2012, DIABETES OBES METAB, V14, P523, DOI 10.1111/j.1463-1326.2011.01554.x
  23. Cercato C, 2019, DIABETOL METAB SYNDR, V11, DOI 10.1186/s13098-019-0468-0
  24. Chakhtoura M, 2023, ECLINICALMEDICINE, V58, DOI 10.1016/j.eclinm.2023.101882
  25. Cheong AJY, 2022, OBESITY, V30, P117, DOI 10.1002/oby.23331
  26. Chiavaroli L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020338
  27. Dahl D, 2022, JAMA-J AM MED ASSOC, V327, P534, DOI 10.1001/jama.2022.0078
  28. Davies MJ, 2018, DIABETES OBES METAB, V20, P734, DOI 10.1111/dom.13125
  29. Davies M, 2021, LANCET, V397, P971, DOI 10.1016/S0140-6736(21)00213-0
  30. Davies MJ, 2022, DIABETES CARE, V45, P2753, DOI 10.2337/dci22-0034
  31. Davies MJ, 2015, JAMA-J AM MED ASSOC, V314, P687, DOI 10.1001/jama.2015.9676
  32. Del Prato S, 2021, LANCET, V398, P1811, DOI 10.1016/S0140-6736(21)02188-7
  33. Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]
  34. Estruch R, 2019, LANCET DIABETES ENDO, V7, pE6, DOI 10.1016/S2213-8587(19)30074-9
  35. Fidler MC, 2011, J CLIN ENDOCR METAB, V96, P3067, DOI 10.1210/jc.2011-1256
  36. Frías JP, 2021, NEW ENGL J MED, V385, P503, DOI 10.1056/NEJMoa2107519
  37. Frias JP, 2018, LANCET, V392, P2180, DOI 10.1016/S0140-6736(18)32260-8
  38. Gadde KM, 2011, LANCET, V377, P1341, DOI 10.1016/S0140-6736(11)60205-5
  39. Garvey WT, 2022, NAT MED, V28, P2083, DOI 10.1038/s41591-022-02026-4
  40. Garvey WT., 2023, Lancet
  41. Gerstein HC, 2019, LANCET, V394, P121, DOI 10.1016/S0140-6736(19)31149-3
  42. Goldberg RB, 2022, CIRCULATION, V145, P1632, DOI 10.1161/CIRCULATIONAHA.121.056756
  43. Gong QH, 2019, LANCET DIABETES ENDO, V7, P452, DOI 10.1016/S2213-8587(19)30093-2
  44. Greenway FL, 2010, LANCET, V376, P595, DOI 10.1016/S0140-6736(10)60888-4
  45. Gregg EW, 2016, LANCET DIABETES ENDO, V4, P913, DOI 10.1016/S2213-8587(16)30162-0
  46. Groenland EH, 2021, INT J CARDIOL, V334, P135, DOI 10.1016/j.ijcard.2021.04.047
  47. Grundy SM, 2019, J AM COLL CARDIOL, V73, P3168, DOI [10.1016/j.jacc.2018.11.002, 10.1161/CIR.0000000000000625]
  48. Halpern B, 2022, ARCH ENDOCRIN METAB, V66, DOI 10.20945/2359-3997000000465
  49. Hollander P, 2013, DIABETES CARE, V36, P4022, DOI 10.2337/dc13-0234
  50. Huang YL, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5953
  51. HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968
  52. Husain M, 2019, NEW ENGL J MED, V381, P841, DOI 10.1056/NEJMoa1901118
  53. Inagaki N, 2022, LANCET DIABETES ENDO, V10, P623, DOI 10.1016/S2213-8587(22)00188-7
  54. James WPT, 2010, NEW ENGL J MED, V363, P905, DOI 10.1056/NEJMoa1003114
  55. Jastreboff AM, 2022, NEW ENGL J MED, V387, P205, DOI 10.1056/NEJMoa2206038
  56. Jastreboff AM, 2023, NEW ENGL J MED, V389, P514, DOI 10.1056/NEJMoa2301972
  57. Kim SH, 2013, DIABETES CARE, V36, P3276, DOI 10.2337/dc13-0354
  58. Knop FK, 2023, LANCET, V402, P705, DOI 10.1016/S0140-6736(23)01185-6
  59. le Roux CW, 2017, LANCET, V389, P1399, DOI 10.1016/S0140-6736(17)30069-7
  60. Leiter LA, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933-019-0871-8
  61. Lopez-Jimenez F, 2022, EUR J PREV CARDIOL, V29, P2218, DOI 10.1093/eurjpc/zwac187
  62. Ludvík B, 2021, LANCET, V398, P583, DOI 10.1016/S0140-6736(21)01443-4
  63. Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827
  64. Mentias A, 2022, J AM COLL CARDIOL, V79, P1429, DOI 10.1016/j.jacc.2022.01.047
  65. Nissen SE, 2016, JAMA-J AM MED ASSOC, V315, P990, DOI 10.1001/jama.2016.1558
  66. O'Neil PM, 2012, OBESITY, V20, P1426, DOI 10.1038/oby.2012.66
  67. Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537
  68. PAN XR, 1993, DIABETES CARE, V16, P150, DOI 10.2337/diacare.16.1.150
  69. Papadaki A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113342
  70. Papamargaritis D, 2022, CARDIOVASC RES, DOI 10.1093/cvr/cvac176
  71. Patoulias D, 2022, AM J CARDIOL, V181, P139, DOI 10.1016/j.amjcard.2022.07.003
  72. Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761
  73. Pi-Sunyer X, 2015, NEW ENGL J MED, V373, P11, DOI 10.1056/NEJMoa1411892
  74. Powell-Wiley TM, 2021, CIRCULATION, V143, pE984, DOI 10.1161/CIR.0000000000000973
  75. Rosenstock J, 2021, LANCET, V398, P143, DOI 10.1016/S0140-6736(21)01324-6
  76. Rubino D, 2021, JAMA-J AM MED ASSOC, V325, P1414, DOI 10.1001/jama.2021.3224
  77. Ryan DH, 2017, CURR OBES REP, V6, P187, DOI 10.1007/s13679-017-0262-y
  78. Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748
  79. Sattar N, 2022, NAT MED, V28, P591, DOI 10.1038/s41591-022-01707-4
  80. Scheen AJ, 2006, LANCET, V368, P1660, DOI 10.1016/S0140-6736(06)69571-8
  81. Simon TG, 2022, GUT, V71, P1867, DOI 10.1136/gutjnl-2021-325724
  82. Sjöström L, 2013, J INTERN MED, V273, P219, DOI 10.1111/joim.12012
  83. Sjöström L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254
  84. Sjöström L, 2012, JAMA-J AM MED ASSOC, V307, P56, DOI 10.1001/jama.2011.1914
  85. Smith SR, 2010, NEW ENGL J MED, V363, P245, DOI 10.1056/NEJMoa0909809
  86. Soriguer F, 2013, J CLIN ENDOCR METAB, V98, P2318, DOI 10.1210/jc.2012-4253
  87. Stumpf MAM, 2023, J CLIN ENDOCR METAB, V108, pE1458, DOI 10.1210/clinem/dgad265
  88. Tolles J, 2016, JAMA-J AM MED ASSOC, V315, P1046, DOI 10.1001/jama.2016.1825
  89. Topol EJ, 2010, LANCET, V376, P517, DOI 10.1016/S0140-6736(10)60935-X
  90. Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155
  91. Vaduganathan M, 2022, LANCET, V400, P757, DOI 10.1016/S0140-6736(22)01429-5
  92. Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X
  93. van Trier TJ, 2022, NETH HEART J, V30, P3, DOI 10.1007/s12471-021-01642-y
  94. van Veldhuisen SL, 2022, EUR HEART J, V43, P1955, DOI 10.1093/eurheartj/ehac071
  95. Verma S, 2018, CIRCULATION, V138, P2884, DOI 10.1161/CIRCULATIONAHA.118.034516
  96. Visseren Frank L J, 2021, Eur Heart J, V42, P3227, DOI 10.1093/eurheartj/ehab484
  97. Wadden TA, 2013, INT J OBESITY, V37, pS1, DOI 10.1038/ijo.2013.89
  98. Wadden TA, 2005, NEW ENGL J MED, V353, P2111, DOI 10.1056/NEJMoa050156
  99. Wadden TA, 2021, JAMA-J AM MED ASSOC, V325, P1403, DOI 10.1001/jama.2021.1831
  100. Wadden TA, 2020, OBESITY, V28, P529, DOI 10.1002/oby.22726
  101. Wadden TA, 2012, CIRCULATION, V125, P1157, DOI 10.1161/CIRCULATIONAHA.111.039453
  102. Wadden TA, 2011, OBESITY, V19, P110, DOI 10.1038/oby.2010.147
  103. Wharton S, 2023, NEW ENGL J MED, DOI 10.1056/NEJMoa2302392
  104. Wilding JPH, 2021, NEW ENGL J MED, V384, P989, DOI 10.1056/NEJMoa2032183
  105. Wilding JPH, 2021, OBES REV, V22, DOI 10.1111/obr.13112
  106. Wilson PWF, 2002, ARCH INTERN MED, V162, P1867, DOI 10.1001/archinte.162.16.1867
  107. Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMoa1812389, 10.1056/NEJMc1902837]
  108. Yau K, 2022, KIDNEY INT REP, V7, P1463, DOI 10.1016/j.ekir.2022.04.094
  109. Yeghiazarians Y, 2021, CIRCULATION, V144, pE56, DOI 10.1161/CIR.0000000000000988
  110. Zhang HM, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2019-000810
  111. Zinman B, 2016, NEW ENGL J MED, V374, P1094, DOI 10.1056/NEJMc1600827

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/10
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - ODS/03